Literature DB >> 18563789

Dose--schedule finding in phase I/II clinical trials using a Bayesian isotonic transformation.

Yisheng Li1, B Nebiyou Bekele, Yuan Ji, John D Cook.   

Abstract

A dose-schedule-finding trial is a new type of oncology trial in which investigators aim to find a combination of dose and treatment schedule that has a large probability of efficacy yet a relatively small probability of toxicity. We demonstrate that a major difference between traditional dose-finding and dose-schedule-finding trials is that while the toxicity probabilities follow a simple nondecreasing order in dose-finding trials, those of dose-schedule-finding trials may adhere to a matrix order. We show that the success of a dose-schedule-finding method requires careful statistical modeling and a sensible dose-schedule allocation scheme. We propose a Bayesian hierarchical model that jointly models the unordered probabilities of toxicity and efficacy and apply a Bayesian isotonic transformation to the posterior samples of the toxicity probabilities, so that the transformed posterior samples adhere to the matrix-order constraints. On the basis of the joint posterior distribution of the order-constrained toxicity probabilities and the unordered efficacy probabilities, we develop a dose-schedule-finding algorithm that sequentially allocates patients to the best dose-schedule combination under certain criteria. We illustrate our methodology through its application to a clinical trial in leukemia and compare it with two alternative approaches. Copyright 2008 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2008        PMID: 18563789      PMCID: PMC4562497          DOI: 10.1002/sim.3329

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  19 in total

1.  Estimating the probability of toxicity at the target dose following an up-and-down design.

Authors:  Mario Stylianou; Michael Proschan; Nancy Flournoy
Journal:  Stat Med       Date:  2003-02-28       Impact factor: 2.373

2.  Bayesian inference on order-constrained parameters in generalized linear models.

Authors:  David B Dunson; Brian Neelon
Journal:  Biometrics       Date:  2003-06       Impact factor: 2.571

3.  Designs for single- or multiple-agent phase I trials.

Authors:  Mark R Conaway; Stephanie Dunbar; Shyamal D Peddada
Journal:  Biometrics       Date:  2004-09       Impact factor: 2.571

Review 4.  Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose.

Authors:  Yuval Shaked; Guido Bocci; Raquel Munoz; Shan Man; John M L Ebos; Daniel J Hicklin; Francesco Bertolini; Robert D'Amato; Robert S Kerbel
Journal:  Curr Cancer Drug Targets       Date:  2005-11       Impact factor: 3.428

5.  A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial.

Authors:  B Nebiyou Bekele; Yu Shen
Journal:  Biometrics       Date:  2005-06       Impact factor: 2.571

6.  Global cross-ratio models for bivariate, discrete, ordered responses.

Authors:  J R Dale
Journal:  Biometrics       Date:  1986-12       Impact factor: 2.571

7.  A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials.

Authors:  P F Thall; K E Russell
Journal:  Biometrics       Date:  1998-03       Impact factor: 2.571

8.  Bivariate isotonic design for dose-finding with ordered groups.

Authors:  Anastasia Ivanova; Kai Wang
Journal:  Stat Med       Date:  2006-06-30       Impact factor: 2.373

9.  Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.

Authors:  Jean-Pierre J Issa; Guillermo Garcia-Manero; Francis J Giles; Rajan Mannari; Deborah Thomas; Stefan Faderl; Emel Bayar; John Lyons; Craig S Rosenfeld; Jorge Cortes; Hagop M Kantarjian
Journal:  Blood       Date:  2003-11-06       Impact factor: 22.113

10.  Continual reassessment method for ordered groups.

Authors:  John O'Quigley; Xavier Paoletti
Journal:  Biometrics       Date:  2003-06       Impact factor: 2.571

View more
  16 in total

1.  Bayesian modeling and prediction of accrual in multi-regional clinical trials.

Authors:  Yi Deng; Xiaoxi Zhang; Qi Long
Journal:  Stat Methods Med Res       Date:  2014-11-03       Impact factor: 3.021

2.  A trivariate continual reassessment method for phase I/II trials of toxicity, efficacy, and surrogate efficacy.

Authors:  Wei Zhong; Joseph S Koopmeiners; Bradley P Carlin
Journal:  Stat Med       Date:  2012-07-16       Impact factor: 2.373

3.  Phase I design for completely or partially ordered treatment schedules.

Authors:  Nolan A Wages; John O'Quigley; Mark R Conaway
Journal:  Stat Med       Date:  2013-09-30       Impact factor: 2.373

4.  A dose-schedule finding design for phase I-II clinical trials.

Authors:  Beibei Guo; Yisheng Li; Ying Yuan
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2016-08-10       Impact factor: 1.864

5.  Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes.

Authors:  Peter F Thall; Hoang Q Nguyen; Thomas M Braun; Muzaffar H Qazilbash
Journal:  Biometrics       Date:  2013-08-19       Impact factor: 2.571

6.  Adaptive Isotonic Estimation of the Minimum Effective and Peak Doses in the Presence of Covariates.

Authors:  Changfu Xiao; Anastasia Ivanova
Journal:  J Stat Plan Inference       Date:  2012-07-01       Impact factor: 1.111

7.  Designs for phase I trials in ordered groups.

Authors:  Mark R Conaway; Nolan A Wages
Journal:  Stat Med       Date:  2016-09-14       Impact factor: 2.373

8.  Bayesian Dose-Finding in Two Treatment Cycles Based on the Joint Utility of Efficacy and Toxicity.

Authors:  Juhee Lee; Peter F Thall; Yuan Ji; Peter Müller
Journal:  J Am Stat Assoc       Date:  2015-06-01       Impact factor: 5.033

9.  Risk-group-specific dose finding based on an average toxicity score.

Authors:  B Nebiyou Bekele; Yisheng Li; Yuan Ji
Journal:  Biometrics       Date:  2009-07-23       Impact factor: 2.571

10.  Phase I/II adaptive design for drug combination oncology trials.

Authors:  Nolan A Wages; Mark R Conaway
Journal:  Stat Med       Date:  2014-01-28       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.